capital raise

Larimar Therapeutics raises $100M through expanded public offering at $5 per share, funding clinical development of rare disease therapeutic candidate nomlabofusp.

Draganfly raises $50M through registered direct offering at $7 per share. Funds will support product development, R&D, and potential strategic acquisitions.

Palvella Therapeutics raised $200M through upsized share offering to fund clinical development of rare disease therapies including skin disease and vascular malformation treatments.

Ideal Power raised $14M to commercialize its B-TRAN semiconductor technology, funding customer design-ins, partnerships, and production infrastructure.

David Tepper criticizes Whirlpool's $963M equity raise and strategic missteps. The activist investor questions capital allocation decisions as stock declines 32% amid housing market weakness.

Intuitive Machines shares fell 16% after announcing a $175M equity raise to fund its $800M Lanteris acquisition, causing significant shareholder dilution.

Immuron lifted H1 revenue 5% to AUD$4.2M with strong U.S. growth of 17%. The company secured AUD$7.3M funding and is pursuing partnerships to advance its clinical pipeline.

Bicara Therapeutics raises $150M through stock and warrant offering to fund lead drug candidate development, expand manufacturing, and build commercial infrastructure.

Bicara Therapeutics plans $150M stock offering to advance its lead drug candidate ficerafusp alfa through clinical development and build commercial infrastructure for potential market launch.

Bimergen Energy raises $13.6M through equity offering to fund battery storage expansion and strengthen operations amid growing grid-scale energy demand.

Eupraxia Pharmaceuticals raises $63.2M to advance its GI disease pipeline, including EP-104GI trials for eosinophilic esophagitis and other gastrointestinal indications.

Candel Therapeutics plans $100M stock offering to fund cancer treatment pipeline development, particularly for prostate and lung cancer therapies.

JIADE Limited launches $3M direct equity offering of 12M shares at $0.25 each. Stock fell 8.13% on announcement; potential $12M if all options exercised.

SKYX secures $33M funding and NVIDIA partnership, expanding retail presence across major chains with projections of 100,000+ units by 2026.

Eupraxia Pharmaceuticals raises $55M via public offering to advance EP-104GI for eosinophilic esophagitis through Phase 2/3 development and expand GI pipeline.

SoFi stock fell 17% in January after a $1.5B capital raise, though the fintech company projects strong 125% net income growth in Q1 2026.

Coherus Oncology raised $50.1M through stock offering to fund commercial launch of LOQTORZI and advance its oncology pipeline development.

Liminatus Pharma prices $4M share offering to fund immuno-oncology pipeline development, specifically advancing CD47-blockade therapeutic programs.

Nasus Pharma raises $15M to advance intranasal epinephrine product toward FDA trials. Funds support NS002 development and pipeline expansion.

Coherus Oncology raises $50.1M via stock offering to fund commercial expansion of LOQTORZI and advance oncology pipeline development programs.